VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq:MNKD) announced today that its End-of-Review (EOR) meeting with the U.S. Food & Drug Administration (FDA) is now scheduled to be held on May 4th. Last Friday, in order to prepare for a potential shutdown of non-critical government operations, the FDA cancelled its internal meeting to prepare for the EOR meeting regarding AFREZZA, necessitating a cancellation of the EOR meeting itself, which had been scheduled for April 15th.
